{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T09:17:51Z","timestamp":1781860671230,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s12185-022-03314-y","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T06:02:31Z","timestamp":1646200951000},"page":"838-851","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis"],"prefix":"10.1007","volume":"115","clinical-trial-number":[{"clinical-trial-number":"nct02130557","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03128411","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00574873","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00261846","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01903733","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00811070","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02228382","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-3787","authenticated-orcid":false,"given":"Naoto","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Sakaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valent\u00edn","family":"Garc\u00eda-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianantonio","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiho","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Ohkura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Tanetsugu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Viqueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,2]]},"reference":[{"key":"3314_CR1","unstructured":"Pfizer Inc. BOSULIF\u00ae (bosutinib) prescribing information. New York, NY; 2017."},{"key":"3314_CR2","unstructured":"Pfizer Japan Inc. BOSULIF\u00ae (bosutinib) prescribing information. Japan; 2020."},{"key":"3314_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","volume":"36","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36:231\u20137.","journal-title":"J Clin Oncol"},{"key":"3314_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s12185-021-03144-4","volume":"114","author":"C Chuah","year":"2021","unstructured":"Chuah C, Koh LP, Numbenjapon T, Zang DY, Ong KH, Do YR, et al. Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. Int J Hematol. 2021;114:65\u201378.","journal-title":"Int J Hematol"},{"key":"3314_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12185-020-02878-x","volume":"112","author":"M Hino","year":"2020","unstructured":"Hino M, Matsumura I, Fujisawa S, Ishizawa K, Ono T, Sakaida E, et al. Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia. Int J Hematol. 2020;112:24\u201332.","journal-title":"Int J Hematol"},{"key":"3314_CR6","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","volume":"30","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kim DW, Kantarjian HM, Brummendorf TH, Dyagil I, Griskevicius L, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30:3486\u201392.","journal-title":"J Clin Oncol"},{"key":"3314_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/bjh.13108","volume":"168","author":"TH Brummendorf","year":"2015","unstructured":"Brummendorf TH, Cortes JE, de Souza CA, Guilhot F, Duvillie L, Pavlov D, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol. 2015;168:69\u201381.","journal-title":"Br J Haematol"},{"key":"3314_CR8","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","volume":"118","author":"JE Cortes","year":"2011","unstructured":"Cortes JE, Kantarjian HM, Brummendorf TH, Kim DW, Turkina AG, Shen ZX, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118:4567\u201376.","journal-title":"Blood"},{"key":"3314_CR9","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3324\/haematol.2017.171249","volume":"103","author":"C Gambacorti-Passerini","year":"2018","unstructured":"Gambacorti-Passerini C, Cortes JE, Lipton JH, Kantarjian HM, Kim DW, Schafhausen P, et al. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I\/II study. Haematologica. 2018;103:1298\u2013307.","journal-title":"Haematologica"},{"key":"3314_CR10","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","volume":"119","author":"HJ Khoury","year":"2012","unstructured":"Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure. Blood. 2012;119:3403\u201312.","journal-title":"Blood"},{"key":"3314_CR11","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1002\/ajh.24536","volume":"91","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Khoury HJ, Kantarjian HM, Lipton JH, Kim DW, Schafhausen P, et al. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and\/or nilotinib. Am J Hematol. 2016;91:1206\u201314.","journal-title":"Am J Hematol"},{"key":"3314_CR12","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/ajh.24034","volume":"90","author":"C Gambacorti-Passerini","year":"2015","unstructured":"Gambacorti-Passerini C, Kantarjian HM, Kim DW, Khoury HJ, Turkina AG, Brummendorf TH, et al. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance\/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol. 2015;90:755\u201368.","journal-title":"Am J Hematol"},{"key":"3314_CR13","doi-asserted-by":"publisher","first-page":"7009","DOI":"10.1200\/JCO.2021.39.15_suppl.7009","volume":"39","author":"C Gambacorti-Passerini","year":"2021","unstructured":"Gambacorti-Passerini C, Br\u00fcmmendorf TH, Kim D-W, Goh YT, Dyagil IS, Pagnano K, et al. Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): final 10-year results of a phase 1\/2 study. J Clin Oncol. 2021;39:7009.","journal-title":"J Clin Oncol"},{"key":"3314_CR14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s12185-014-1722-8","volume":"101","author":"C Nakaseko","year":"2015","unstructured":"Nakaseko C, Takahashi N, Ishizawa K, Kobayashi Y, Ohashi K, Nakagawa Y, et al. A phase 1\/2 study of bosutinib in Japanese adults with philadelphia chromosome-positive chronic myeloid leukemia. Int J Hematol. 2015;101:154\u201364.","journal-title":"Int J Hematol"},{"key":"3314_CR15","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s12185-017-2239-8","volume":"106","author":"N Takahashi","year":"2017","unstructured":"Takahashi N, Nakaseko C, Kobayashi Y, Miyamura K, Ono C, Koide Y, et al. Long-term treatment with bosutinib in a phase 1\/2 study in Japanese chronic myeloid leukemia patients resistant\/intolerant to prior tyrosine kinase inhibitor treatment. Int J Hematol. 2017;106:398\u2013410.","journal-title":"Int J Hematol"},{"key":"3314_CR16","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1038\/s41375-020-0915-9","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Gambacorti-Passerini C, Abboud C, Gjertsen BT, Brummendorf TH, Smith BD, et al. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia. 2020;34:2125\u201337.","journal-title":"Leukemia"},{"key":"3314_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/JBM.S129821","volume":"9","author":"S Isfort","year":"2018","unstructured":"Isfort S, Brummendorf TH. Bosutinib in chronic myeloid leukemia: patient selection and perspectives. J Blood Med. 2018;9:43\u201350.","journal-title":"J Blood Med"},{"key":"3314_CR18","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/annonc\/mdy019","volume":"29","author":"HJ Khoury","year":"2018","unstructured":"Khoury HJ, Gambacorti-Passerini C, Brummendorf TH. Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia. Ann Oncol. 2018;29:578\u201387.","journal-title":"Ann Oncol"},{"key":"3314_CR19","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/ajh.24360","volume":"91","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Jean Khoury H, Kantarjian H, Brummendorf TH, Mauro MJ, Matczak E, et al. Long-term evaluation of cardiac and vascular toxicity in patients with philadelphia chromosome-positive leukemias treated with bosutinib. Am J Hematol. 2016;91:606\u201316.","journal-title":"Am J Hematol"},{"key":"3314_CR20","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/ejh.13608","volume":"106","author":"JE Cortes","year":"2021","unstructured":"Cortes JE, Kantarjian HM, Mauro MJ, An F, Nick S, Leip E, et al. Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy. Eur J Haematol. 2021;106:808\u201320.","journal-title":"Eur J Haematol"},{"key":"3314_CR21","unstructured":"European Medicines Agency. BOSULIF\u00ae (bosutinib) summary of product characteristics. London, UK; 2018."},{"key":"3314_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13045-018-0685-2","volume":"11","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Apperley JF, DeAngelo DJ, Deininger MW, Kota VK, Rousselot P, et al. Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. J Hematol Oncol. 2018;11:143.","journal-title":"J Hematol Oncol"},{"key":"3314_CR23","doi-asserted-by":"publisher","first-page":"E66","DOI":"10.1002\/ajh.23938","volume":"90","author":"J Cortes","year":"2015","unstructured":"Cortes J, Mauro M, Steegmann JL, Saglio G, Malhotra R, Ukropec JA, et al. Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: data from the FDA adverse event reporting system. Am J Hematol. 2015;90:E66-72.","journal-title":"Am J Hematol"},{"key":"3314_CR24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.blre.2018.01.004","volume":"32","author":"BC Medeiros","year":"2018","unstructured":"Medeiros BC, Possick J, Fradley M. Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: strategies for monitoring, detecting, and managing. Blood Rev. 2018;32:289\u201399.","journal-title":"Blood Rev"},{"key":"3314_CR25","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","volume":"2","author":"J Douxfils","year":"2016","unstructured":"Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogne JM. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis. JAMA Oncol. 2016;2:625\u201332.","journal-title":"JAMA Oncol"},{"key":"3314_CR26","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.leukres.2007.01.024","volume":"31","author":"M Breccia","year":"2007","unstructured":"Breccia M, Muscaritoli M, Gentilini F, Latagliata R, Carmosino I, Rossi Fanelli F, et al. Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. Leuk Res. 2007;31:1770\u20132.","journal-title":"Leuk Res"},{"key":"3314_CR27","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.3324\/haematol.2014.104075","volume":"99","author":"D Rea","year":"2014","unstructured":"Rea D, Mirault T, Cluzeau T, Gautier JF, Guilhot F, Dombret H, et al. Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Haematologica. 2014;99:1197\u2013203.","journal-title":"Haematologica"},{"key":"3314_CR28","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1182\/blood-2019-121815","volume":"134","author":"BT Gjertsen","year":"2019","unstructured":"Gjertsen BT, Hochhaus A, Rosti G, Watts JM, Ort\u00ed G, le Coutre P, et al. Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: BYOND phase 4 study. Blood. 2019;134:1639.","journal-title":"Blood"},{"key":"3314_CR29","doi-asserted-by":"crossref","unstructured":"Gambacorti-Passerini C, Lipton JH, Hochhaus A, Kota VK, Baccarani M, Durrant S, et al. Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors in patients with Philadelphia chromosome-positive leukemia: phase 1\/2 study update. Presented at: Annual Meeting of the American Society of Clinical Oncology (ASCO); June 1\u20135, 2018; Chicago, IL.","DOI":"10.1200\/JCO.2018.36.15_suppl.7062"},{"key":"3314_CR30","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333\u201340.","journal-title":"J Clin Oncol"},{"key":"3314_CR31","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s12185-017-2208-2","volume":"105","author":"H Nakamae","year":"2017","unstructured":"Nakamae H, Fujisawa S, Ogura M, Uchida T, Onishi Y, Taniwaki M, et al. Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report. Int J Hematol. 2017;105:792\u2013804.","journal-title":"Int J Hematol"},{"key":"3314_CR32","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1182\/blood-2013-10-532341","volume":"123","author":"NP Shah","year":"2014","unstructured":"Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Brummendorf TH, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014;123:2317\u201324.","journal-title":"Blood"},{"key":"3314_CR33","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","volume":"125","author":"D Montani","year":"2012","unstructured":"Montani D, Bergot E, Gunther S, Savale L, Bergeron A, Bourdin A, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125:2128\u201337.","journal-title":"Circulation"},{"key":"3314_CR34","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1182\/blood-2018-99-110798","volume":"132","author":"MW Deininger","year":"2018","unstructured":"Deininger MW, Kota V, Lipton JH, Milojkovic D, Garc\u00eda Guti\u00e9rrez V, Leip E, et al. Bosutinib or imatinib in older vs younger patients with newly diagnosed chronic myeloid leukemia in the phase 3 BFORE trial. Blood. 2018;132:1734.","journal-title":"Blood"},{"key":"3314_CR35","first-page":"2899","volume":"130","author":"M Garrett","year":"2017","unstructured":"Garrett M, Knight B, Cortes JE, Deininger MW. Optimizing dose of bosutinib to minimize adverse events while maintaining efficacy in patients with newly diagnosed chronic myelogenous leukemia. Blood. 2017;130:2899.","journal-title":"Blood"},{"key":"3314_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40164-018-0101-1","volume":"7","author":"A Mita","year":"2018","unstructured":"Mita A, Abumiya M, Miura M, Niioka T, Takahashi S, Yoshioka T, et al. Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia. Exp Hematol Oncol. 2018;7:9.","journal-title":"Exp Hematol Oncol"},{"key":"3314_CR37","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s12185-017-2238-9","volume":"106","author":"A Tojo","year":"2017","unstructured":"Tojo A, Kyo T, Yamamoto K, Nakamae H, Takahashi N, Kobayashi Y, et al. Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1\/2 study. Int J Hematol. 2017;106:385\u201397.","journal-title":"Int J Hematol"},{"key":"3314_CR38","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s12185-011-0841-8","volume":"93","author":"H Nakamae","year":"2011","unstructured":"Nakamae H, Shibayama H, Kurokawa M, Fukuda T, Nakaseko C, Kanda Y, et al. Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd. Int J Hematol. 2011;93:624\u201332.","journal-title":"Int J Hematol"},{"key":"3314_CR39","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.3109\/10428194.2013.866663","volume":"55","author":"CT Chuah","year":"2014","unstructured":"Chuah CT, Nakamae H, Shen ZX, Bradley-Garelik MB, Kim DW. Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase. Leuk Lymphoma. 2014;55:2093\u2013100.","journal-title":"Leuk Lymphoma"},{"key":"3314_CR40","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00228-011-1200-7","volume":"68","author":"RA Larson","year":"2012","unstructured":"Larson RA, Yin OQ, Hochhaus A, Saglio G, Clark RE, Nakamae H, et al. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol. 2012;68:723\u201333.","journal-title":"Eur J Clin Pharmacol"},{"key":"3314_CR41","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1182\/blood.V114.22.1127.1127","volume":"114","author":"D-W Kim","year":"2009","unstructured":"Kim D-W, Granvil C, Demirhan E, Reynolds J, Jin Y, Wang Y, et al. Comparison of steady-state imatinib (IM) trough levels, clinical response, and safety between Caucasian and Asian patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with 400mg and 800mg daily doses of IM in the tyrosine kinase inhibitor optimization and selectivity (TOPS) study. Blood. 2009;114:1127.","journal-title":"Blood"},{"key":"3314_CR42","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/ajh.23973","volume":"90","author":"V Garcia-Gutierrez","year":"2015","unstructured":"Garcia-Gutierrez V, Martinez-Trillos A, Lopez Lorenzo JL, Bautista G, Martin Mateos ML, Alvarez-Larran A, et al. Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program. Am J Hematol. 2015;90:429\u201333.","journal-title":"Am J Hematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03314-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03314-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03314-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T13:33:16Z","timestamp":1654090396000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03314-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,2]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["3314"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03314-y","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,2]]},"assertion":[{"value":"5 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Naoto Takahashi reports research funding from Novartis, Otsuka, Pfizer, Asahi Kasei, Astellas Pharma, and Ono Pharmaceutical, and speakers bureau with Novartis, Otsuka, Pfizer, and Bristol Myers Squibb. Jorge E. Cortes reports consultancy with Amphivena Therapeutics, Astellas Pharma, Bio-Path Holdings Inc, BiolineRx, Bristol Myers Squibb, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis, Pfizer, and Takeda, and research funding from Astellas Pharma, Bristol Myers Squibb, Daiichi Sankyo, Immunogen, Jazz Pharmaceuticals, Merus, Novartis, Pfizer, Sun Pharma, Takeda, Tolero Pharmaceuticals, and Trovagene. Emiko Sakaida reports research funding from Bristol Myers Squibb, Chugai, Kyowa Kirin, Ono, and Pfizer. Kenichi Ishizawa reports research funding from Novartis, AbbVie, Bayer, SymBio, Otsuka, Pfizer, Takeda, and Kyowa Kirin, and speakers bureau with Takeda, Celgene, Ono, Novartis, Chugai, and Eisai. Takaaki Ono reports honoraria from Bristol Myers Squibb, Celgene, Merck Sharp & Dohme, Novartis, Ono, Otsuka, Pfizer, and Takeda, and research funding from Celgene, Chugai, Kyowa Hakko Kirin, Merck Sharp & Dohme, Ono, and Pfizer. Itaru Matsumura reports speakers bureau with Amgen Astellas BioPharma K.K., Astellas Pharma, Bristol Myers Squibb, Daiichi Sankyo, Janssen Pharmaceutical K.K., Novartis Pharma K.K., Otsuka Pharmaceutical, Pfizer Japan Inc, and research funding from AbbVie G.K., Asahi Kasei Pharma, Chugai Pharmaceutical, Eisai, Japan Blood Products Organization, Kyowa Kirin, Mitsubishi Tanabe Pharma, MSD K.K., Nippon Shinyaku, Ono Pharmaceutical, Shionogi, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, and Takeda.. Valent\u00edn Garc\u00eda-Guti\u00e9rrez reports consultancy with Bristol Myers Squibb, Incyte, Novartis, and Pfizer, and research funding from Pfizer. Gianantonio Rosti reports research funding from Pfizer, and speakers bureau with Bristol Myers Squibb, Incyte, Novartis, and Pfizer. Chiho Ono reports employment by and stock options with Pfizer. Masayuki Ohkura and Yusuke Tanetsugu report employment by Pfizer R&D Japan G.K. Andrea Viqueira reports employment by and stock ownership in Pfizer. Tim H. Br\u00fcmmendorf reports consultancy with Janssen, Merck, Novartis, and Pfizer, research funding from Novartis and Pfizer, and honoraria from Novartis and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}